Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors
© Ates et al. 2016
Received: 9 April 2016
Accepted: 11 April 2016
Published: 19 April 2016
The aims of this study were to comprehensively describe the psychosocial and medical characteristics of women who initiated tamoxifen or aromatase inhibitors for breast cancer and to compare levels of emotional distress according to their medical (tumor demographics, treatment type, treatment duration) and psychosocial (self-esteem, perceived social support, sociodemographic) characteristics.
A total of 104 women currently receiving tamoxifen or aromatase inhibitors was recruited from outpatient clinics and they were asked to complete self-report questionnaires including the Rosenberg Self-Esteem Scale, the Multidimensional Scale of Perceived Social Support and the Hospital Anxiety and Depression Scale during their routine follow-up. Psychosocial and medical characteristics of the patients were first described and subsequently the score of emotional distress was compared with these.
The patients’ mean age was 52.49 ± 10.30 and they were being treated for an average of 24.3 months. Out of the patients’ characteristics, educational and marital status, level of perceived social support and self-esteem were all significantly related with emotional distress. As for medical variables, the score of distress was relatively higher among patients in the first 2 years of their treatment than the patients who were in the second to fifth years of treatment, but this was not statistically significant.
Given the results of this study, it appeared that patient variables, rather than the medical or treatment characteristics, were related with emotional distress in women undergoing endocrine treatment. For that reason it is critical that medical staff are aware of patient factors that relate to distress during a long period of adjuvant endocrine therapy.
KeywordsBreast cancer Endocrine therapy Emotional distress Psychosocial factors Social support Self-esteem
Breast cancer is a major public health problem that affects women in many parts of the world as well as Turkey (Ferlay et al. 2015). Breast cancer treatments have substantially improved over the past two decades, which have led to a reduction in breast cancer mortality due to both screening and improvements in therapy (Berry et al. 2005).
Approximately 70 % of all breast cancers are hormone receptor positive (Harvey et al. 1999) and in this group of patients, upon completion of primary therapy (e.g., surgery, radiation, chemotherapy), adjuvant endocrine therapy (AET) with either tamoxifen or aromatase inhibitors (AIs) is an important component (Early Breast Cancer Trialists’ Collaborative Group 2005). The widely accepted standard for AET for hormone receptor positive breast lesions for many years was the administration of tamoxifen for the duration of 5 years (Howell et al. 2005). However with the development of the third-generation AIs (i.e. anastrozole, letrozole and exemestane) the use of tamoxifen was replaced in postmenopausal patients (Smith and Dowsett 2003). A lot of studies indicated that both regimens, tamoxifen and AIs, are appropriate treatment options in these patients as they reduce risk of disease relapse and death (Burstein et al. 2014; Regan et al. 2011).
Although AET can improve disease-free survival in breast cancer patients, some studies indicated that it is associated with considerable side effects that negatively impact women’s well-being (von Blanckenburg et al. 2013). During AET, many breast cancer patients can experience a range of physical and psychological side effects such as hot flushes, joint pain and emotional distress (ED) (Rosenberg et al. 2015; van Londen et al. 2014; Bower 2008). Distress is a multifactorial unpleasant emotional experience of a psychological, social and/or spiritual nature that may interfere with the ability to cope effectively with cancer, its symptoms and its physical treatment (National Comprehensive Cancer Network 2011). While most of the previous studies focused on the physical adverse effects in women taking AET, very few studies addressed the emotional problems such as anxiety and depression among these patients (Rosenberg et al. 2015). From these limited studies, Ploos van Amstel et al. 2013 conducted research among breast cancer survivors of whom 37 % were still treated with hormonal therapy and showed that one-third of all cancer survivors experienced distress. However in a different study, it was reported that depression scores were within the normal range in patients treated with tamoxifen or raloxifene in comparison to healthy women in similar age group (Land et al. 2006). More specifically, Schilder et al. (2009) evaluated symptoms of depression in breast cancer patients treated with tamoxifen or exemestane and healthy control groups and researchers indicated that there were no differences between patients and control groups with regard to mental health or depressive symptoms.
The objectives of our cross-sectional study were to describe comprehensively the psychosocial characteristics of patients and to investigate the relationship between psychosocial and medical characteristics and self-reported ED in women with breast cancer who are on tamoxifen or aromatase inhibitors. Knowledge about this relationship is fundamental to develop necessary interventions to reduce ED in women during the long treatment journey. Psychosocial factors were assessed by evaluating self-esteem, perceived social support and patients’ sociodemographic characteristics including age, marital status, number of children, level of education, socioeconomic status, body mass index and menopausal status at diagnosis. Illness and treatment-related factors were assessed by evaluating a broad range of medical factors such as type and duration of AET, type of surgery, tumor stage and grade, and administration of chemotherapy or radiotherapy. Most of the included medical and psychosocial parameters in this study have not been investigated in previous studies.
We employed a cross-sectional, descriptive, and correlational design. Participants were recruited consecutively between September 2015 and December 2015 during their routine outpatient clinic visits in Hacettepe University, Institute of Oncology. Patients were considered eligible for participation if they were diagnosed with non-metastatic (stages I–III) hormone receptor-positive breast cancer, had completed their surgical treatment, chemotherapy, and/or radiation therapy and were currently taking adjuvant endocrine therapy (tamoxifen or AIs) for at least 1 month. All included patients were female, older than 18 years of age and had graduated from primary school or higher. Patients were excluded if they were taking AET as part of treatment for metastatic disease or had documented psychiatric or neurological disorders that could interfere with study participation (e.g., dementia or schizophrenia).
Of the 130 women approached, 87 % agreed to participate. A further nine agreed participants had to be excluded due to the following reasons: 4 women took AET for less than 1 month and 5 women did not complete the study questionnaire despite their consent. 104 women were included in the final analysis.
The study was approved by the ethical committee of the Hacettepe University, Faculty of Medicine. The researcher and medical oncologists read relevant medical records to search for potential patients in order to decide patients’ eligibility for this study. Patients who passed this pre-screening were informed and the purpose of the study was explained to them by their oncologists at the time of routine medical follow-up. When patients agreed to participate in the study, they were contacted by the study research assistant who provided further information. They were informed that their involvement was voluntary and they could withdraw from the study any time without affecting their care. After written and verbal informed consent was obtained from each participant, data regarding their age, educational and marital status, number of children, and socioeconomic status was asked during face-to-face interviews using a demographic questionnaire. Subsequently, patients completed self-report questionnaires. If possible, we requested patients to complete the questionnaire without assistance and support was given only when it was necessary. The medical information including tumor stage and grade, menopausal status, type of surgery, type and duration of AET, and administration of chemotherapy and/or radiotherapy was obtained from medical records.
Demographic and Clinical Questionnaire
Socio-demographic and medical characteristics of patients (n = 104)
Cancer and treatment factors
Age [mean (min–max)]
Time (months) since AET initiation
Between 1 and 24 months
Between 25 and 58 months
One or more
Aromatase inhibitors (AIs)c
Primary or secondary school
College or above
Pathological tumor stage
Body mass index (kg/m2)
Type of surgery
Peri or post-menopausal
Breast conserving surgery
Hospital Anxiety and Depression Scale (HADs)
This is a self-reported scale originally developed to indicate the possible presence of anxiety and depression states (Zigmond and Snaith 1983). It contains two subscales (one for anxiety and the one for depression) and 14 items. Total scores for each subscale range from 0 to 21, and higher scores represent greater anxiety or depression. The Turkish version of this scale was assessed by Aydemir et al. (1997) for its validity and reliability (Aydemir et al. 1997). Aydemir et al. (1997) stated that the Cronbach alpha was 0.85 and 0.77 for anxiety and depression subscales respectively. In this study the Cronbach alpha was 0.84 in the anxiety subscale and 0.80 in the depression subscale.
While the HADs scale is accepted as valid and reliable in cancer patients and is used frequently as a standard in the field of clinical oncology/psychology services (Vodermaier and Millman 2011), recent studies have indicated that it does not provide a good separation between symptoms of anxiety and depression (Norton et al. 2013). However it is effective in measuring the level of emotional distress (Norton et al. 2013; Cosco et al. 2012). For that reason we decided to use the ‘HADs Total’ in emotional distress calculations.
Multidimensional Scale of Perceived Social Support (MSPSS)
The MSPSS was used to measure the level of perceived social support from family, friends, and significant others. It contains 12 items and each item is rated on a 7 point scale. (Zimet et al. 1988). All items are added and then divided by 12 for the total score. High scores indicate a high degree of perceived social support. Its validity and reliability in Turkey was performed by Eker and Arkar (1995) and the Cronbach alpha was 0.89 (Eker and Arkar 1995). In this this study the Cronbach alpha was found to be 0.88.
Rosenberg Self-Esteem Scale (RSES)
This scale measures global self-esteem with a 10-item scale based on direct self-reporting (Rosenberg 1965). Possible scores of the scale range from 10 to 40. Higher scores represent more positive attitudes toward the self. This scale was adapted to the Turkish population by Cuhadaroglu (1986) and the correlation between the scale and psychiatric interview results was found to be 0.71 and the test–retest reliability was reported as 0.75 (Cuhadaroglu 1986). For the present study, the Cronbach alpha of the scale was 0.85.
Based on the previous studies, we divided the total patients into two groups: Group one comprised patients having AET for a duration of between 1 and 24 months and group two comprised patients on AET between 25 and 60 months. Such a division was performed as some researchers have indicated that breast cancer survivors experience more distress in the first 2 years than in the period between 2 and 5 years (Ploos van Amstel et al. 2013). Therefore, we expected that ED might be higher during the first 2 years of AET compared to the second period.
All data was analyzed using SPSS software version 22 for Windows. The patients’ sociodemographic and clinical characteristics were summarized with means, standard deviations, ranges, and frequencies in order to provide a description of the sample of patients. The associations between sociodemographic and clinical variables were assessed using the Mann–Whitney U test and Kruskal–Wallis statistics on the data distribution. In cases of a significant difference among three groups, the Post Hoc Mann–Whitney U test was used to compare the three groups on dependent variables, using a Bonferonni corrected p value of 0.017 to indicate statistical significance. Relationships between ED, self-esteem, social support and age were examined by the Spearman product moment correlation coefficients.
Socio-demographic and medical characteristics of the patients are listed in Table 1. The mean age was 52.49 (SD ± 10.30) years. Seventy-nine (75.9 %) patients were married, and 86 (82.7 %) had one or more children. Approximately two-thirds of women (66.4 %) had been educated at high school level or above. The majority of participants (70.2 %) reported their socio-economic status as middle class. Roughly 70 % of participants had a BMI within the overweight or obesity category and more than half of women (53.8 %) were peri- or post-menopausal. With regards to treatment, the duration of AET for the overall sample ranged from 1 to 58 months (Mean = 24.38, SD = 18.26). More than half were taking AIs (52.9 %), and the remaining women were taking tamoxifen (47.1 %) at the time of participation in this study. Before AET treatment, 71.2 % of women received radiotherapy and 61.5 % received chemotherapy. With regards to the primary breast tumor and grade, nearly half of the patients were reported as T2 and grade II (51 and 49 % respectively). Fifty-nine patients (56.7 %) underwent mastectomy, while the remainder had breast-conserving surgery.
Relationship between emotional distress and patients’ socio-demographic and clinical factors
Distributions of level of psychological distress according to medical and sociodemographic characteristics of patients
HAD total mean ± SE
HAD total mean ± SE
13.17 ± 7.87
13.65 ± 8.30
19.12 ± 10.47
Aromatase inhibitors (AI)
15.45 ± 9.37
MWU = 704, p = 0.031
MWU = 1223, p = 0.417
Duration of AET
One or More
14.36 ± 8.53
Between 1 and 24 months
16.01 ± 9.19
15.77 ± 10.60
Between 25 and 58 months
13.24 ± 8.45
MWU = 761, p = 0.911
MWU = 1073, p = 0.070
Pathological tumor stage
Primary or secondary
18.68 ± 9.57
15.40 ± 9.28
12.38 ± 7.23
14.30 ± 8.83
College or above
12.68 ± 8.43
12.66 ± 7.77
KW = 9.489, p = 0.009
KW = 0.589, p = 0.745
Body mass index
12.48 ± 7.12
12.91 ± 9.11
14.33 ± 9.65
15.60 ± 8.98
17.41 ± 9.08
13.85 ± 8.77
KW = 4.188, p = 0.123
KW = 1.750, p = 0.417
Type of surgery
13.50 ± 8.43
14.66 ± 8.76
Peri or post-menopausal
15.55 ± 9.23
Breast conserving surgery
14.53 ± 9.14
MWU = 1194, p = 0.329
MWU = 1308, p = 0.901
16.05 ± 10.11
71.2 (74)/28.8 (30)
14.97 ± 8.97/13.70 ± 8.75
14.24 ± 8.69
MWU = 1020, p = 0.520
14.61 ± 8.73
KW = 0.512, p = 0.774
61.5 (64)/38.5 (40)
15.21 ± 9.02/13.62 ± 8.69
MWU = 1129, p = 0.314
Relationship between self-esteem, perceived social support and emotional distress
Means, SDs, and correlations among study variables
1. Psychological distress
2. Perceived social support
3. Self esteem
4. Age of patients
After the completion of primary treatment, patients with breast cancer often receive long-term AET to reduce disease recurrence and to improve survival; therefore, awareness about their psychological experiences is important in this long duration of treatment. For that reason, we designed the current study to provide a more detailed picture of the psychosocial characteristics of women undergoing AET and focused on the relationship between these factors and levels of ED.
Mehnert and Koch (2008) indicated that lower education is a predictor of psychological comorbidity in patients with breast cancer. Conversely Gómez-Campelo et al. 2014 reported that having a higher educational level was associated with more psychological distress. In our study, in line with Menhert and Koch, we found that patients who completed primary or secondary school were significantly more likely to have a higher level of ED than those who had completed high school and college or above. Our findings might be explained by the fact that patients with higher educational levels may have more awareness about recent advances in treatment options from different sources such as the Internet, and as a result have less psychological distress. However more research is needed to elucidate the effect of education on ED. In addition to level of education, we found that single patients reported more distress than those who were married. It can be speculated that married women may have more physical support from their spouses or children compared to those who are single. Physical support may be important in dealing with problems such as transportation, particularly when patients are having aggressive treatment. Married women may also be less exposed to stressful life situations than single women due to their greater financial power. Therefore, unmarried patients might have experienced higher ED levels. Consistent with our study, Giese-Davis et al. 2012 indicated that unmarried women are particularly vulnerable to experiencing practical and psychosocial problems while being married protects against such problems.
In previous studies, some researchers indicated that anxiety and depressive symptoms were not significantly affected by endocrine therapy during the first 3 years of treatment (Nystedt et al. 2003). In a different study, Land et al. 2006 investigated symptoms of depression over a period of 60 months and demonstrated that the depression score remained unchanged during the entire course of treatment (Land et al. 2006). In our study, while the difference was not at the statistical level, we found that women who were taking AET revealed higher ED in their first 2 years of treatment compared to those who were within the 25th to 60th months. This difference of lower ED levels at the late (3- to 5-year) period may be secondary to the fact that more time has elapsed since the initial aggressive treatments (i.e. surgery, chemo and radiotherapy). Future research is required to clarify the relationship between ED and duration of AET. In addition to these findings, in line with previous studies, our study showed no significant difference in ED score between patients treated with tamoxifen and those who were treated with AIs (Schilder et al. 2009; Takei et al. 2012; Ohsumi et al. 2011).
Perceived social support has been established as protective factor, which mitigates psychological distress in breast cancer patients (Friedman et al. 2006). In accordance with that study, our data revealed that perceived social support and self-esteem were negatively related with emotional distress. These findings also support the results of Brunet et al. (2014) that perceived support could be one way to help patients to cope with stress. In the light of these studies, medical staff should identify patients who have low perceived social support and self-esteem and refer them to psycho-oncology units.
Our study has some limitations. It has a cross-sectional design which provides no information on causal relationship. For that reason, longitudinal studies are required to establish more clearly the causal relationship between distress, patient related factors and medical characteristics and future studies are also needed to examine mediating/moderating effects of the identified risk factors. In addition, we did not evaluate the data regarding the comorbidities of patients. Despite these limitations, our study is noteworthy because we broadly assessed the range of factors that related with distress along with perceived social support and self-esteem.
Implications for clinical practice
Patient-reported outcomes are particularly useful in the setting of prevention. In this respect, outcomes of the present study will assist in the design of interventions to prevent or manage the psychological mood of patients with breast cancer on AET. The current findings suggest that professionals need to continuously assess and monitor depressive and anxiety symptoms in breast cancer patients after initiation of AET especially if they factors related to high levels of ED as described above. As several recent studies have already identified that high distress is a risk factor for poorer medical adherence of AET (Cahir et al. 2015; Colleoni et al. 2000), our study results are of significance to ensure the continuation of treatment by detecting potential patients who may be prone to have higher distress in a timely fashion.
OA, CS, TB, FS, NK, KA contributed to study conception. OA, CS, KA contributed towards data acquisition. OA, CS, TB, KA, ARS, contributed towards data analysis and interpretation. OA, CS, TB, FS, NK, ARS, DA, KA contributed to the study design, and to drafting of the manuscript, revising it critically for important intellectual content and giving final approval of the version to be published. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Aydemir O, Guvenir T, Kuey L et al (1997) The validity and reliability of the Turkish version of hospital anxiety and depression scale. Turkish Psychiatry 8:280–287Google Scholar
- Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792View ArticleGoogle Scholar
- Bower JE (2008) Behavioral symptoms in breast cancer patients and survivors: fatigue, insomnia, depression, and cognitive disturbance. J Clin Oncol 26:768–777View ArticleGoogle Scholar
- Brunet J, Love C, Ramphal R et al (2014) Stress and physical activity in young adults treated for cancer: the moderating role of social support. Support Care Cancer 22:689–695View ArticleGoogle Scholar
- Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32:2255–22698View ArticleGoogle Scholar
- Cahir C, Guinan E, Dombrowski SU et al (2015) Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I–III breast cancer: a systematic review and meta-analysis. Patient Educ Couns. doi:https://doi.org/10.1016/j.pec.2015.05.013 Google Scholar
- Colleoni M, Mandala M, Peruzzotti G et al (2000) Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 356:1326–1327View ArticleGoogle Scholar
- Cosco TD, Doyle F, Ward M et al (2012) Latent structure of the Hospital Anxiety And Depression Scale: a 10-year systematic review. J Psychosom Res 72:180–184View ArticleGoogle Scholar
- Cuhadaroglu F (1986) Self-esteem in adolescents. PhD thesis. Hacettepe University Medical School, AnkaraGoogle Scholar
- Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717View ArticleGoogle Scholar
- Eker D, Arkar H (1995) Perceived social support: psychometric properties of the MSPSS in normal and pathological groups in a developing country. Soc Psychiatry Psychiatr Epidemiol 30:121–126View ArticleGoogle Scholar
- Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:359–386View ArticleGoogle Scholar
- Friedman LC, Kalidas M, Elledge R et al (2006) Optimism, social support and psychosocial functioning among women with breast cancer. Psychooncology 15:595–603View ArticleGoogle Scholar
- Giese-Davis J, Waller A, Carlson LE et al (2012) Screening for distress, the 6th vital sign: common problems in cancer outpatients over one year in usual care: associations with marital status, sex, and age. BMC Cancer 12:441. doi:https://doi.org/10.1186/1471-2407-12-441 View ArticleGoogle Scholar
- Gómez-Campelo P, Bragado-Álvarez C, Hernández-Lloreda José et al (2014) Psychological distress in women with breast and gynecological cancer treated with radical surgery. Psychooncology 23:459–466View ArticleGoogle Scholar
- Harvey JM, Clark GM, Osborne CK et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481Google Scholar
- Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62View ArticleGoogle Scholar
- Land SR, Wickerham DL, Costantino JP et al (2006) Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2742–2751View ArticleGoogle Scholar
- Mehnert A, Koch U (2008) Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res 64:383–391View ArticleGoogle Scholar
- National Comprehensive Cancer Network (2011) NCCN clinical practice guidelines in oncology: distress management. USGoogle Scholar
- Norton S, Cosco T, Doyle F et al (2013) The Hospital Anxiety and Depression Scale: a meta confirmatory factor analysis. J Psychosom Res 74:74–81View ArticleGoogle Scholar
- Nystedt M, Berglund G, Bolund C et al (2003) Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 21:1836–1844View ArticleGoogle Scholar
- Ohsumi S, Shimozuma K, Ohashi Y et al (2011) Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1–4 years: N-SAS BC 03. Breast Cancer Res Tr 127:143–152View ArticleGoogle Scholar
- Ploos van Amstel FK, van den Berg SW, van Laarhoven HW et al (2013) Distress screening remains important during follow-up after primary breast cancer treatment. Support Care Cancer 21:2107–2115View ArticleGoogle Scholar
- Regan MM, Neven P, Giobbie-Hurder A et al (2011) Evaluating letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomized clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101–1108View ArticleGoogle Scholar
- Rosenberg M (1965) Society and the adolescent self-Image. Princeton University Press, New JerseyGoogle Scholar
- Rosenberg SM, Stanton AL, Petrie KJ et al (2015) Symptoms and symptom attribution among women on endocrine therapy for breast cancer. Oncologist 20:598–604View ArticleGoogle Scholar
- Schilder CM, Eggens PC, Seynaeve C et al (2009) Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 48:76–85View ArticleGoogle Scholar
- Smith Ian E, Dowsett Mitch (2003) Aromatase Inhibitors in Breast Cancer. N Engl J Med 348:2431–2442View ArticleGoogle Scholar
- Takei H, Ohsumi S, Shimozuma K et al (2012) Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Tr 133:227–236View ArticleGoogle Scholar
- van Londen GJ, Beckjord EB, Dew MA et al (2014) Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer 22:937–945View ArticleGoogle Scholar
- Vodermaier A, Millman RD (2011) Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: a systematic review and meta-analysis. Support Care Cancer 19:1899–1908View ArticleGoogle Scholar
- von Blanckenburg P, Schuricht F, Albert US et al (2013) Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer 13:426View ArticleGoogle Scholar
- Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370View ArticleGoogle Scholar
- Zimet GD, Dahlem NW, Zimet SG et al (1988) The multidimensional scale of perceived social support. J Pers Assess 52:30–41View ArticleGoogle Scholar